Top 5 Prefered Stocks To Own Right Now

Charitable giving by Americans in 2013 probably increased by 13% over 2012, Atlas of Giving said in a recent report on November totals.

The outlook for the next 12 months is less optimistic, however, with an expected increase of 5.5%, the report said.

At the end of November, charitable giving amounted to $380 billion, compared with $338 billion a year ago — a 12.4% rise — and was expected to end the year at $417 billion, ahead of last year’s $369 billion.

Charitable gift sources, whose proportions have remained steady since 2011, will be the same in 2013, the report said:

Religion will again be the biggest giving sector in 2013, accounting for 35% of total contributions.

Education and health will retain the next two spots, at 16% and 8% of total giving, respectively.

Human/disaster services, 12% of total sector giving, will show the largest increase in 2013, up 18.7%.

---

Check out 3 Charity Strategies to Cope With Rising Taxes on ThinkAdvisor.

Best Life Sciences Stocks To Invest In Right Now: Vishay Precision Group Inc.(VPG)

Vishay Precision Group, Inc. designs, manufactures, and markets components based on resistive foil technology, sensors, and sensor-based systems in the United States, Europe, and Asia. The company?s products include precision foil resistors, foil strain gages, transducers and load cells, modules, instruments, weighing and control systems, and PhotoStress coatings and instruments; and sensors that convert mechanical inputs into an electronic signal for display, processing, interpretation, or control by the company?s instrumentation and systems products. Its products are used in waste management, bulk hauling, logging, scales manufacturing, engineering systems, pharmaceutical, oil, chemical, steel, paper, and food industries, as well as in military/aerospace, medical, agriculture, and construction markets. The company sells its products through original equipment manufacturers, electronic manufacturing services companies, and independent distributors, as well as directly t o end-use customers. Vishay Precision Group, Inc. was founded in 1962 and is headquartered in Malvern, Pennsylvania.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Vishay Precision Group (NYSE: VPG  ) , whose recent revenue and earnings are plotted below.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Vishay Precision Group (NYSE: VPG  ) , whose recent revenue and earnings are plotted below.

Top 5 Prefered Stocks To Own Right Now: Haemonetics Corp (HAE)

Haemonetics Corporation, incorporated on August 29, 1985, is a healthcare company engaged in providing blood management solutions to its customers. The Company�� portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.

The Company helps its customers create and maintain a safe and efficient blood supply chain. Specifically, it develops and markets a wide range of systems used with plasma and blood donors that collect and process blood into its components using both manual and automated methods. It also develops and markets a variety of systems to hospitals that automate the cleaning and reinfusion of a surgical patient's blood during surgery, automate the tracking and distribution of blood in the hospital, and enhance blood diagnostics. The Company sells information technology platforms to promote efficient and compliant operations for all of its customer groups. The Company provides consulting services to reduce costs and improve operating efficiencies in blood management. . Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does.

Plasma

Human plasma is collected and processed by bio-ph! armaceutical companies into therapeutic and diagnostic products that aid in the treatment of immune diseases and coagulation disorders. While plasma is also used to aid patients with extreme blood loss, such as trauma victims, this portion of its business solely focuses on plasma's pharmaceutical uses. Automated plasma collection technology allows for the safe and efficient collection of plasma. The Company manufactures and market plasma collection devices and respective disposables, but do not make plasma-derived pharmaceuticals.

The Company�� portfolio of products and services is designed to support multiple facets of plasma collector operations. The Company with its PCS brand automated plasma collection technology, more plasma can be collected during any one donation event because the other blood components are returned to the donor through the sterile disposable sets used for the plasma donation procedure. The Company offers one stop shopping to its plasma collection customers, enabling them to source from them the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. It also offers a robust portfolio of integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain. Its products automate the donor interview and qualification process; streamline the workflow process in the plasma center; provide the controls necessary to evaluate donor suitability; determine the ability to release units collected; and manage unit distribution.

Blood Center

The Company offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products.The Company markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components integrated from the donor. Utilizing t! he MCS au! tomated platelet collection protocols, blood centers collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor. The MCS two-unit protocol or double red cell collection device helps blood collectors optimize the collection of red cells by automating the blood separation function, eliminating the need for laboratory processing, and enabling the collection of two units of red cells from a single donor thus maximizing the amount of red cells collected per eligible donor and helping to mitigate red cell shortages in countries where this problem exists. Blood collectors can also use the MCS system to collect one unit of red cells and a jumbo (double) unit of plasma, or one unit of red cells and one unit of platelets from a single donor. The MCS plasma protocol providing the possibility to collect 600-800ml of plasma for transfusion to patients or for pharmaceutical industry use completes the comprehensive portfolio of different blood component collection options on this device.

The Company offers a portfolio of products for manual whole blood collection and processing. Haemonetics' portfolio of disposable whole blood collection and component storage sets offer flexibility in collecting a unit of whole blood and the subsequent production and storage of the red blood cell, platelet, and/or plasma products, including options for in-line or dockable filters for leukoreduction of any blood component. In addition Acrodose product line provides a closed system for the pooling, storage, and bacteria testing of leukoreduced whole blood derived platelet concentrates, an Acrodose Platelet, that is transfusion ready for the hospital. Use of Acrodose platelets lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital.

The Company with ACP(Automated Cell Processor) brand offers a small bench-top solution to automate the washing and freezing of red cell components in the lab. The automated red cell was! hing proc! edure removes plasma proteins within the red cell units to provide a safer product for transfusion to frequently transfused patients, neonates, or patients with a history of transfusion reactions. The automated glycerolization and deglycerolization steps are required to prepare red cells for frozen storage. Freezing the red cell units can expand the shelf life of these products up to 10 years. Customers utilize this technology to implement strategic red cell inventories for catastrophe cases, storage of rare blood types, or enhanced inventory management.

Hospital

The Company offers a range of blood management solutions that significantly improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it efficiently and correctly. Its products and integrated solution platforms help hospitals optimize performance of blood acquisition, storage, and distribution.The Company�� TEG Thrombelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots.

The Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. During the year ended December 31,2012, the Company launched the Cell Saver Elite system, which is autotransfusion option to minimize allogeneic blood use for surgeries with medium to high blood loss. The OrthoPAT surgical blood salvage system is targeted to procedures, such as orthopedic, that involve slower, lower volume blood loss that often occurs well after surgery. The cardioPAT system is a surgical blood salvage system targeted to open heart surgeries when there is less blood loss during surgery, but where the blood loss continues post-surgery. These systems are designed to remain with the patient following surgery, to recover blood and produce a washed red cell produ! ct for au! totransfusion. Their Quick-Connect feature permits customers to utilize the blood processing set selectively, depending on the patient's need.

The Company�� IMPACT Online Web-based software platform, which monitors and measures improvements in a hospital�� blood management practices, provides hospitals with a baseline view of their blood management metrics and helps monitor transfusion rates. Business consulting solutions are offered to support process and blood management efforts. It also provides blood management assessment tools to hospitals that enables its customers to monitor their progress in order to continually improve their blood management performance.

Software Solutions

The Companby has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. For its plasma customers, it also provides information technology platforms for managing donors and information associated with the collection of plasma products within fractionation facilities.

The Company�� software solutions , including information technology platforms and consulting services can be combined with its devices and sold through its plasma, blood center, and hospital sales forces. The Company�� software products help hospitals track and safely deliver stored blood products. SafeTrace Tx is its software solution that helps manage blood product inventory, perform patient cross-matching, and manage transfusions. In addition, its BloodTrack suite of solutions manages tracking and control of blood products from the hospital blood center through to transfusion to the patient. Smart refrigerators located in or near operating suites, emergency rooms, and other parts of the hospital dispense blood units with secure control and autom! ated trac! eability for efficient documentation. With its offerings, hospitals are better able to manage processes across the blood supply chain and identify increased opportunities to reduce costs and enhance processes. Its software solutions, such as its SafeTrace and El Dorado Donor donation and blood unit management systems, span blood center operations and automate and track operations from the recruitment of the blood donor to the disposition of the blood product. Its Hemasphere software solution provides support for more efficient blood drive planning, and Donor Doc and e-Donor software help to improve recruitment and retention.

The Company competes with Fenwal, Inc., Terumo BCT ,Caridian BCT, Rotem, MAK Systems, Mediware, MacoPharma , Medtronic, Fresenius, Sunquest Information Systems and Sorin Biomedica.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Haemonetics (NYSE: HAE  ) , whose recent revenue and earnings are plotted below.

• [By Jake L'Ecuyer]

  Haemonetics (NYSE: HAE) tumbled 1.13 percent to $42.06 after analysts at Benchmark downgraded the stock from Buy to Hold and lowered the target price from $49 to $46.

• [By Holly LaFon]

  Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power.

Top 5 Prefered Stocks To Own Right Now: FNB United Corp.(FNBN)

FNB United Corp. operates as the bank holding company for CommunityONE Bank, National Association that provides consumer, mortgage, and business banking services to individual and business customers in North Carolina. Its deposit products include checking accounts, interest checking accounts, money market accounts, savings accounts, certificates of deposit, and individual retirement accounts. The company?s loan products portfolio comprises commercial and agricultural loans, real estate construction loans, real estate residential loans, and consumer loans. It also offers debit cards, credit cards, online and mobile banking, cash management, investment management, and trust services, as well as operates automated teller machines. In addition, it originates, underwrites, and closes loans for sale into the secondary market. FNB United operates through 45 offices. The company was formerly known as FNB Corp. and changed its name to FNB United Corp. in April 2006. FNB United Cor p. was founded in 1907 and is headquartered in Asheboro, North Carolina.

Advisors' Opinion:

• [By Holly LaFon]

  The second stock, FNB United Corp. (FNBN), is 95.4% off of its three-year high, but it has also had a stock split in that time. It has also seen greater insider activity. Five unique insiders bought shares of the company, for a total number of six insider buy transactions in the past month.

Top 5 Prefered Stocks To Own Right Now: Old Dominion Freight Line Inc. (ODFL)

Old Dominion Freight Line, Inc. operates as a less-than-truckload (LTL) motor carrier primarily in the United States. The company provides regional, inter-regional, and national LTL services. It also offers a range of logistics services, including ground and air expedited transportation, supply chain consulting, transportation management, truckload brokerage, container delivery, and warehousing services. In addition, the company provides door-to-door international freight services to and from North America, Central America, South America, and the Far East. As of December 31, 2010, it owned a fleet of 5,718 tractors and 20,986 trailers, as well as operated 213 service centers. The company was founded in 1934 and is based in Thomasville, North Carolina.

Advisors' Opinion:

• [By Ben Levisohn]

  Wunderlich’s Nicholas Bender thinks FedEx’s results bode well for Old Dominion (ODFL), Con-way (CNW) and Saia (SAIA):

  We expect all less-than-truckload carriers to benefit in 2Q14 from the same trends that carried FedEx Freight to a banner 4Q14. This includes Hold-rated Old Dominion, which will continue to grow at well above market rates, and Buy-rated Con-way, which we believe can leverage a strong 2Q14 to prime the pump on margin enhancement efforts. Our favorite name in the space remains Saia (SAIA-$42.92, Buy), which will once again see accelerating tonnage growth in 2Q14. Though tonnage growth will moderate in� 2H14 due to steeper comps, there remains considerable potential for the company to boost yield and continue winning incremental business with new accounts.

• [By Rich Smith]

  Consider: According to YRC, the $150.9 million it currently pays in annual interest exceeds the $92.6 million in interest obligations paid by "all [of its] competitors combined." Con-Way (NYSE: CNW  ) , for example, sports a debt load about half of YRC's, yet pays only about one-third �as much in interest on that debt. Old Dominion Freight (NASDAQ: ODFL  ) has 12% the debt �of YRC, but only 7% of the interest expense.